We previously reported manageable toxicities and high efficacy with HBI0101, in a frailer and higher-risk MM patient population as compared with other anti-BCMA CAR-T studies, including an overall response rate of 92% and a median progression-free survival of 11.6 months [8]. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.